Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094523 · ClinicalTrials.gov registry record · Phase 3
Fosamprenavir Versus Other Protease Inhibitors
A Phase 3 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
NCT00094523 is a Phase 3 study that has completed, run by ViiV Healthcare. The registered enrollment target is 314 participants.
The verdict
NCT00094523, a Phase 3 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
Study Summary
This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir. This is a 48-week study, where subjects who were assigned to be in their original PI-group have the option of switching to fosamprenavir on week 24. Prior to being assigned their treatment group, subjects had to be suppressed for at least three months. All subjects also take a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors.
Interventions
- DRUG Fosamprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2004-12-14 |
| Est. Completion | 2007-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094523
The ClinicalTrials.gov registry entry for NCT00094523 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fosamprenavir is the first listed.
NCT00094523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00094523 about?
NCT00094523 is a clinical study titled "Fosamprenavir Versus Other Protease Inhibitors". This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir. This is a 48-week study, where subjects who were assigned to be in their original PI-group have the option of switching to ...
What is the current status of trial NCT00094523?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2004-12-14. Estimated completion is 2007-06-29.
What interventions are being tested in trial NCT00094523?
The interventions under investigation include: Fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00094523?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.